Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Staphylococcal wall teichoic acids (WTA) and peptidoglycan (PG) are the primary structural components of the Gram-positive cell wall in species such as Staphylococcus epidermidis and Staphylococcus saprophyticus (Nature Reviews Microbiology, 2013, 11(3):181-91). Peptidoglycan provides the mechanical strength required to withstand osmotic pressure, while WTA are anionic polymers that regulate ion homeostasis, cell division, and surface adhesion (StatPearls, 2023, Bacterial Cell Wall). These components are critical for the survival and virulence of staphylococci, facilitating biofilm formation and evasion of the host immune system (Journal of Bacteriology, 2010, 192(12):3033-3041). In clinical practice, these structures are the primary targets for several classes of antibiotics, including beta-lactams and glycopeptides, which disrupt the synthesis or assembly of the cell wall (PubMed, PMID: 23348754). Beta-lactams inhibit the cross-linking of peptidoglycan strands, whereas glycopeptides like vancomycin bind to the D-Ala-D-Ala terminus of the peptidoglycan precursor (PubChem, CID 14969). Emerging therapies also focus on inhibiting WTA biosynthesis enzymes, such as TarO, to sensitize resistant strains to existing antibiotics. The structural diversity of WTA across different staphylococcal species presents a challenge for developing broad-spectrum inhibitors. Furthermore, fragments of these cell wall components can act as pathogen-associated molecular patterns (PAMPs), triggering inflammatory responses through Toll-like receptor 2.
Inhibition of peptidoglycan cross-linking by binding to penicillin-binding proteins (PBPs), sequestration of D-alanyl-D-alanine precursors, or inhibition of wall teichoic acid biosynthesis enzymes such as TarO and TarG.
6 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Staphylococcal wall teichoic acid and peptidoglycan (WTA-PG).